Compare RL & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RL | RVMD |
|---|---|---|
| Founded | 1967 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Apparel | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2B | 19.2B |
| IPO Year | 1997 | N/A |
| Metric | RL | RVMD |
|---|---|---|
| Price | $380.41 | $96.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 17 |
| Target Price | ★ $403.87 | $120.47 |
| AVG Volume (30 Days) | 555.9K | ★ 1.6M |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 19.57 | N/A |
| EPS | ★ 12.66 | N/A |
| Revenue | ★ $7,079,000,000.00 | N/A |
| Revenue This Year | $15.95 | N/A |
| Revenue Next Year | $5.80 | $411.49 |
| P/E Ratio | $30.40 | ★ N/A |
| Revenue Growth | ★ 6.75 | N/A |
| 52 Week Low | $196.57 | $34.00 |
| 52 Week High | $387.65 | $124.49 |
| Indicator | RL | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 62.27 | 48.24 |
| Support Level | $323.20 | $93.39 |
| Resistance Level | N/A | $101.00 |
| Average True Range (ATR) | 11.60 | 3.12 |
| MACD | 5.75 | 0.21 |
| Stochastic Oscillator | 89.37 | 51.05 |
Founded by designer Ralph Lauren (current executive chairman and chief creative officer) in 1967 in New York City, Ralph Lauren Corp. designs, markets, and distributes lifestyle merchandise in North America, Europe, and Asia. Best known for its iconic polo shirts, its products also include other types of apparel, footwear, eyewear, jewelry, handbags, home goods, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, and Lauren Ralph Lauren. Distribution channels for Ralph Lauren include wholesale (department stores and specialty stores), retail (company-owned retail stores and e-commerce), and licensing.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.